Profile Details

Create Project

★★★★★

☆☆☆☆☆

USD 40 /hr

★★★★★

☆☆☆☆☆

Hire Esteban T.

United States

USD 40 /hr

Discovery Biologist and Platform Developer showcasing 8+ years of experience in biotech industry and academia

Profile Summary

Strategic thinker and cross-functional communicator with ample experience leading projects as a specialist in early drug discovery, platform development, and oncology. Proven track record of establishing research laboratories, conceiving and executing cell-based and biochemical assays, leading external projects in collaboration with CROs and academic partners. In my most recent role as a Principal Scientist, I have directed and contributed to several large-scale projects. I played a leadership role in the completion of two independent projects focused on oncology and rare disease, culminating in their publication in peer-reviewed journals. I managed direct reports conducting in-house exploratory research and led collaborations with CROs to characterize the mechanism of action (MoA) of Eloxx's lead compounds. Additionally, I directed the design, set-up, and procurement of equipment to establish fully operational Biology and Tissue Culture laboratories while overseeing a Research and Operations Associates team. My Ph.D. work (University of North Carolina at Chapel Hill) focused on the discovery of a novel self-interaction facilitator (SIF) domain in the Drosophila Mxc protein involved in the accumulation and formation of the histone locus body (HLB). As a Post-Doctoral Research Fellow (Vanderbilt University Medical Center) I led projects and collaborated with a multi-institutional team interrogating the role of the methyltransferase SETD2 in renal cell carcinoma cancer, culminating in the publication of 3 articles in peer-reviewed journals. Throughout my career, I have designed and developed diverse molecular and cellular assays, have employed confocal microscopy techniques, and have used liquid handlers and automated systems.

Subject Matter Expertise

• ★ Cell-Based Assays
• ★ Data Analysis
• ★ High Throughput Screening (HTS)
• ☆ Biochemistry
• ☆ Immunoassay
• ☆ Biochemical Assays
• ☆ Apoptosis
• ☆ Molecular Biology
• ☆ Genetics
• ☆ PCR
• ☆ Molecular Cloning
• ☆ DNA Sequencing
• ☆ Gene Expression Analysis
• ☆ Recombinant DNA
• ☆ Plasmid DNA
• ☆ Cell Biology
• ☆ Gene Regulation
• ☆ Microscopy
• ☆ Light Microscopy
• ☆ Fluorescence Microscopy
• ☆ Big Data Analytics
• ☆ Data Management
• ☆ Data Manipulation
• ☆ Text Mining & Analytics
• ☆ Data Mining
• ☆ Data Cleaning
• ☆ Cell Culture
• ☆ Primary Cells
• ☆ Cell Line Engineering
• ☆ 3D Cell Culture
• ☆ Blotting
• ☆ Immunohistochemistry
• ☆ SQL
• ☆ Excel
• ☆ R
• ☆ Tableau
• ☆ Drug Discovery
• ☆ Drug Target Identification
• ☆ Hit-to-Lead & Lead Optimization
• ☆ Technical & Scientific Writing

Services

• Writing
• Research
• Consulting
• Data & AI

Writing Technical Writing, Audio Transcription, Translation

Research Scientific and Technical Research

Consulting Scientific and Technical Consulting

Data & AI Data Visualization, Big Data Analytics, Text Mining & Analytics, Data Cleaning, Data Processing, Data Insights

Work Experience

Principal Scientist

Eloxx Pharmaceuticals

February 2022 - May 2023

Research Scientist II

Eloxx Pharmaceuticals

March 2020 - January 2022

Research Scientist I

Eloxx Pharmaceuticals

June 2019 - February 2020

Research Scientist

Broad Institute

April 2019 - May 2019

Scientist

Constellation Pharmaceuticals

May 2018 - March 2019

Post-doctoral Research Fellow

Vanderbilt University Medical Center

February 2016 - April 2018

Graduate Research Assistant

University of North Carolina - Chapel Hill

September 2009 - February 2016

Education

PhD - Genetics and Molecular Biology

University of North Carolina - Chapel Hill

September 2009 - December 2015

Certifications

• Business Intelligence

  Google

  https://www.coursera.org/account/accomplishments/professional-cert/HD967K7N5UQP

  February 2024 - April 2024

• Data Analytics Professional Certificate

  Google

  https://www.coursera.org/account/accomplishments/professional-cert/M82RXU9NLAR2

  June 2023 - February 2024

Publications

JOURNAL ARTICLE

Esteban Terzo, Shruti A. Apte, Simran Padhye, Saleh Rashed, Wesley Austin, Michael Caponegro, Anupama Reddy, Shuhao Shi, Christy Wang, Roger B. Clark, et al. (2023). A Novel Class of Ribosome Modulating Agents Exploits Cancer Ribosome Heterogeneity to Selectively Target the CMS2 Subtype of Colorectal Cancer . Cancer Research Communications.

PREPRINT

Esteban Terzo, Shruti A. Apte, Simran Padhye, Saleh Rashed, Wesley Austin, Michael Caponegro, Anupama Reddy, Shuhao Shi, Christy Wang, Roger B. Clark, et al. (2023). Data from A Novel Class of Ribosome Modulating Agents Exploits Cancer Ribosome Heterogeneity to Selectively Target the CMS2 Subtype of Colorectal Cancer .

Esteban Terzo, Shruti A. Apte, Simran Padhye, Saleh Rashed, Wesley Austin, Michael Caponegro, Anupama Reddy, Shuhao Shi, Christy Wang, Roger B. Clark, et al. (2023). Data from A Novel Class of Ribosome Modulating Agents Exploits Cancer Ribosome Heterogeneity to Selectively Target the CMS2 Subtype of Colorectal Cancer .

Esteban Terzo, Shruti A. Apte, Simran Padhye, Saleh Rashed, Wesley Austin, Michael Caponegro, Anupama Reddy, Shuhao Shi, Christy Wang, Roger B. Clark, et al. (2023). FIGURE 1 from A Novel Class of Ribosome Modulating Agents Exploits Cancer Ribosome Heterogeneity to Selectively Target the CMS2 Subtype of Colorectal Cancer .

Esteban Terzo, Shruti A. Apte, Simran Padhye, Saleh Rashed, Wesley Austin, Michael Caponegro, Anupama Reddy, Shuhao Shi, Christy Wang, Roger B. Clark, et al. (2023). FIGURE 1 from A Novel Class of Ribosome Modulating Agents Exploits Cancer Ribosome Heterogeneity to Selectively Target the CMS2 Subtype of Colorectal Cancer .

Esteban Terzo, Shruti A. Apte, Simran Padhye, Saleh Rashed, Wesley Austin, Michael Caponegro, Anupama Reddy, Shuhao Shi, Christy Wang, Roger B. Clark, et al. (2023). FIGURE 2 from A Novel Class of Ribosome Modulating Agents Exploits Cancer Ribosome Heterogeneity to Selectively Target the CMS2 Subtype of Colorectal Cancer .

Esteban Terzo, Shruti A. Apte, Simran Padhye, Saleh Rashed, Wesley Austin, Michael Caponegro, Anupama Reddy, Shuhao Shi, Christy Wang, Roger B. Clark, et al. (2023). FIGURE 2 from A Novel Class of Ribosome Modulating Agents Exploits Cancer Ribosome Heterogeneity to Selectively Target the CMS2 Subtype of Colorectal Cancer .

Esteban Terzo, Shruti A. Apte, Simran Padhye, Saleh Rashed, Wesley Austin, Michael Caponegro, Anupama Reddy, Shuhao Shi, Christy Wang, Roger B. Clark, et al. (2023). FIGURE 3 from A Novel Class of Ribosome Modulating Agents Exploits Cancer Ribosome Heterogeneity to Selectively Target the CMS2 Subtype of Colorectal Cancer .

Esteban Terzo, Shruti A. Apte, Simran Padhye, Saleh Rashed, Wesley Austin, Michael Caponegro, Anupama Reddy, Shuhao Shi, Christy Wang, Roger B. Clark, et al. (2023). FIGURE 3 from A Novel Class of Ribosome Modulating Agents Exploits Cancer Ribosome Heterogeneity to Selectively Target the CMS2 Subtype of Colorectal Cancer .

Esteban Terzo, Shruti A. Apte, Simran Padhye, Saleh Rashed, Wesley Austin, Michael Caponegro, Anupama Reddy, Shuhao Shi, Christy Wang, Roger B. Clark, et al. (2023). FIGURE 4 from A Novel Class of Ribosome Modulating Agents Exploits Cancer Ribosome Heterogeneity to Selectively Target the CMS2 Subtype of Colorectal Cancer .

Esteban Terzo, Shruti A. Apte, Simran Padhye, Saleh Rashed, Wesley Austin, Michael Caponegro, Anupama Reddy, Shuhao Shi, Christy Wang, Roger B. Clark, et al. (2023). FIGURE 5 from A Novel Class of Ribosome Modulating Agents Exploits Cancer Ribosome Heterogeneity to Selectively Target the CMS2 Subtype of Colorectal Cancer .

Esteban Terzo, Shruti A. Apte, Simran Padhye, Saleh Rashed, Wesley Austin, Michael Caponegro, Anupama Reddy, Shuhao Shi, Christy Wang, Roger B. Clark, et al. (2023). Figure S1 from A Novel Class of Ribosome Modulating Agents Exploits Cancer Ribosome Heterogeneity to Selectively Target the CMS2 Subtype of Colorectal Cancer .

Esteban Terzo, Shruti A. Apte, Simran Padhye, Saleh Rashed, Wesley Austin, Michael Caponegro, Anupama Reddy, Shuhao Shi, Christy Wang, Roger B. Clark, et al. (2023). FIGURE 5 from A Novel Class of Ribosome Modulating Agents Exploits Cancer Ribosome Heterogeneity to Selectively Target the CMS2 Subtype of Colorectal Cancer .

Esteban Terzo, Shruti A. Apte, Simran Padhye, Saleh Rashed, Wesley Austin, Michael Caponegro, Anupama Reddy, Shuhao Shi, Christy Wang, Roger B. Clark, et al. (2023). FIGURE 4 from A Novel Class of Ribosome Modulating Agents Exploits Cancer Ribosome Heterogeneity to Selectively Target the CMS2 Subtype of Colorectal Cancer .

Esteban Terzo, Shruti A. Apte, Simran Padhye, Saleh Rashed, Wesley Austin, Michael Caponegro, Anupama Reddy, Shuhao Shi, Christy Wang, Roger B. Clark, et al. (2023). Figure S1 from A Novel Class of Ribosome Modulating Agents Exploits Cancer Ribosome Heterogeneity to Selectively Target the CMS2 Subtype of Colorectal Cancer .

Esteban Terzo, Shruti A. Apte, Simran Padhye, Saleh Rashed, Wesley Austin, Michael Caponegro, Anupama Reddy, Shuhao Shi, Christy Wang, Roger B. Clark, et al. (2023). Figure S2 from A Novel Class of Ribosome Modulating Agents Exploits Cancer Ribosome Heterogeneity to Selectively Target the CMS2 Subtype of Colorectal Cancer .

Esteban Terzo, Shruti A. Apte, Simran Padhye, Saleh Rashed, Wesley Austin, Michael Caponegro, Anupama Reddy, Shuhao Shi, Christy Wang, Roger B. Clark, et al. (2023). Figure S3 from A Novel Class of Ribosome Modulating Agents Exploits Cancer Ribosome Heterogeneity to Selectively Target the CMS2 Subtype of Colorectal Cancer .

Esteban Terzo, Shruti A. Apte, Simran Padhye, Saleh Rashed, Wesley Austin, Michael Caponegro, Anupama Reddy, Shuhao Shi, Christy Wang, Roger B. Clark, et al. (2023). Figure S3 from A Novel Class of Ribosome Modulating Agents Exploits Cancer Ribosome Heterogeneity to Selectively Target the CMS2 Subtype of Colorectal Cancer .

Esteban Terzo, Shruti A. Apte, Simran Padhye, Saleh Rashed, Wesley Austin, Michael Caponegro, Anupama Reddy, Shuhao Shi, Christy Wang, Roger B. Clark, et al. (2023). Supplementary Data 1 from A Novel Class of Ribosome Modulating Agents Exploits Cancer Ribosome Heterogeneity to Selectively Target the CMS2 Subtype of Colorectal Cancer .

Esteban Terzo, Shruti A. Apte, Simran Padhye, Saleh Rashed, Wesley Austin, Michael Caponegro, Anupama Reddy, Shuhao Shi, Christy Wang, Roger B. Clark, et al. (2023). Supplementary Data 1 from A Novel Class of Ribosome Modulating Agents Exploits Cancer Ribosome Heterogeneity to Selectively Target the CMS2 Subtype of Colorectal Cancer .

Esteban Terzo, Shruti A. Apte, Simran Padhye, Saleh Rashed, Wesley Austin, Michael Caponegro, Anupama Reddy, Shuhao Shi, Christy Wang, Roger B. Clark, et al. (2023). Supplementary Methods 1 from A Novel Class of Ribosome Modulating Agents Exploits Cancer Ribosome Heterogeneity to Selectively Target the CMS2 Subtype of Colorectal Cancer .

Esteban Terzo, Shruti A. Apte, Simran Padhye, Saleh Rashed, Wesley Austin, Michael Caponegro, Anupama Reddy, Shuhao Shi, Christy Wang, Roger B. Clark, et al. (2023). Figure S2 from A Novel Class of Ribosome Modulating Agents Exploits Cancer Ribosome Heterogeneity to Selectively Target the CMS2 Subtype of Colorectal Cancer .

Esteban Terzo, Shruti A. Apte, Simran Padhye, Saleh Rashed, Wesley Austin, Michael Caponegro, Anupama Reddy, Shuhao Shi, Christy Wang, Roger B. Clark, et al. (2023). Supplementary Methods 1 from A Novel Class of Ribosome Modulating Agents Exploits Cancer Ribosome Heterogeneity to Selectively Target the CMS2 Subtype of Colorectal Cancer .

Esteban Terzo, Shruti A. Apte, Simran Padhye, Saleh Rashed, Wesley Austin, Michael Caponegro, Anupama Reddy, Shuhao Shi, Christy Wang, Roger B. Clark, et al. (2023). Supplementary Table 1 from A Novel Class of Ribosome Modulating Agents Exploits Cancer Ribosome Heterogeneity to Selectively Target the CMS2 Subtype of Colorectal Cancer .

Esteban Terzo, Shruti A. Apte, Simran Padhye, Saleh Rashed, Wesley Austin, Michael Caponegro, Anupama Reddy, Shuhao Shi, Christy Wang, Roger B. Clark, et al. (2023). Supplementary Table 1 from A Novel Class of Ribosome Modulating Agents Exploits Cancer Ribosome Heterogeneity to Selectively Target the CMS2 Subtype of Colorectal Cancer .

Esteban Terzo, Shruti A. Apte, Simran Padhye, Saleh Rashed, Wesley Austin, Michael Caponegro, Anupama Reddy, Shuhao Shi, Christy Wang, Roger B. Clark, et al. (2023). TABLE 1 from A Novel Class of Ribosome Modulating Agents Exploits Cancer Ribosome Heterogeneity to Selectively Target the CMS2 Subtype of Colorectal Cancer .

Esteban Terzo, Shruti A. Apte, Simran Padhye, Saleh Rashed, Wesley Austin, Michael Caponegro, Anupama Reddy, Shuhao Shi, Christy Wang, Roger B. Clark, et al. (2023). TABLE 1 from A Novel Class of Ribosome Modulating Agents Exploits Cancer Ribosome Heterogeneity to Selectively Target the CMS2 Subtype of Colorectal Cancer .

Esteban Terzo, Shruti A Apte, Simran Padhye, Saleh Rashed, Wesley Austin, Michael Caponegro, Anupama Reddy, Shuhao Shi, Christy Wang, Roger B Clark, et al. (2023). Data from A novel class of Ribosome Modulating Agents (RMAs) exploits cancer ribosome heterogeneity to selectively target the CMS2 subtype of colorectal cancer .

Esteban Terzo, Shruti A Apte, Simran Padhye, Saleh Rashed, Wesley Austin, Michael Caponegro, Anupama Reddy, Shuhao Shi, Christy Wang, Roger B Clark, et al. (2023). Figure S1 from A novel class of Ribosome Modulating Agents (RMAs) exploits cancer ribosome heterogeneity to selectively target the CMS2 subtype of colorectal cancer .

Esteban Terzo, Shruti A Apte, Simran Padhye, Saleh Rashed, Wesley Austin, Michael Caponegro, Anupama Reddy, Shuhao Shi, Christy Wang, Roger B Clark, et al. (2023). Supplementary Data 1 from A novel class of Ribosome Modulating Agents (RMAs) exploits cancer ribosome heterogeneity to selectively target the CMS2 subtype of colorectal cancer .

Esteban Terzo, Shruti A Apte, Simran Padhye, Saleh Rashed, Wesley Austin, Michael Caponegro, Anupama Reddy, Shuhao Shi, Christy Wang, Roger B Clark, et al. (2023). Supplementary Data 1 from A novel class of Ribosome Modulating Agents (RMAs) exploits cancer ribosome heterogeneity to selectively target the CMS2 subtype of colorectal cancer .

Esteban Terzo, Shruti A Apte, Simran Padhye, Saleh Rashed, Wesley Austin, Michael Caponegro, Anupama Reddy, Shuhao Shi, Christy Wang, Roger B Clark, et al. (2023). Supplementary Methods 1 from A novel class of Ribosome Modulating Agents (RMAs) exploits cancer ribosome heterogeneity to selectively target the CMS2 subtype of colorectal cancer .

Esteban Terzo, Shruti A Apte, Simran Padhye, Saleh Rashed, Wesley Austin, Michael Caponegro, Anupama Reddy, Shuhao Shi, Christy Wang, Roger B Clark, et al. (2023). Figure S1 from A novel class of Ribosome Modulating Agents (RMAs) exploits cancer ribosome heterogeneity to selectively target the CMS2 subtype of colorectal cancer .

Esteban Terzo, Shruti A Apte, Simran Padhye, Saleh Rashed, Wesley Austin, Michael Caponegro, Anupama Reddy, Shuhao Shi, Christy Wang, Roger B Clark, et al. (2023). Figure S3 from A novel class of Ribosome Modulating Agents (RMAs) exploits cancer ribosome heterogeneity to selectively target the CMS2 subtype of colorectal cancer .

Esteban Terzo, Shruti A Apte, Simran Padhye, Saleh Rashed, Wesley Austin, Michael Caponegro, Anupama Reddy, Shuhao Shi, Christy Wang, Roger B Clark, et al. (2023). Figure S2 from A novel class of Ribosome Modulating Agents (RMAs) exploits cancer ribosome heterogeneity to selectively target the CMS2 subtype of colorectal cancer .

Esteban Terzo, Shruti A Apte, Simran Padhye, Saleh Rashed, Wesley Austin, Michael Caponegro, Anupama Reddy, Shuhao Shi, Christy Wang, Roger B Clark, et al. (2023). Supplementary Methods 1 from A novel class of Ribosome Modulating Agents (RMAs) exploits cancer ribosome heterogeneity to selectively target the CMS2 subtype of colorectal cancer .

Esteban Terzo, Shruti A Apte, Simran Padhye, Saleh Rashed, Wesley Austin, Michael Caponegro, Anupama Reddy, Shuhao Shi, Christy Wang, Roger B Clark, et al. (2023). Supplementary Table 1 from A novel class of Ribosome Modulating Agents (RMAs) exploits cancer ribosome heterogeneity to selectively target the CMS2 subtype of colorectal cancer .

Esteban Terzo, Shruti A Apte, Simran Padhye, Saleh Rashed, Wesley Austin, Michael Caponegro, Anupama Reddy, Shuhao Shi, Christy Wang, Roger B Clark, et al. (2023). Figure S3 from A novel class of Ribosome Modulating Agents (RMAs) exploits cancer ribosome heterogeneity to selectively target the CMS2 subtype of colorectal cancer .

Esteban Terzo, Shruti A Apte, Simran Padhye, Saleh Rashed, Wesley Austin, Michael Caponegro, Anupama Reddy, Shuhao Shi, Christy Wang, Roger B Clark, et al. (2023). Figure S2 from A novel class of Ribosome Modulating Agents (RMAs) exploits cancer ribosome heterogeneity to selectively target the CMS2 subtype of colorectal cancer .

Esteban Terzo, Shruti A Apte, Simran Padhye, Saleh Rashed, Wesley Austin, Michael Caponegro, Anupama Reddy, Shuhao Shi, Christy Wang, Roger B Clark, et al. (2023). Supplementary Table 1 from A novel class of Ribosome Modulating Agents (RMAs) exploits cancer ribosome heterogeneity to selectively target the CMS2 subtype of colorectal cancer .